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Chapman W Palweni, Audino Podda, Michael Whitfield, Sanet Aspinall 
Objectives. Haemophilus influenzae type b (Hib) infection 
remains a major public health problem inthe developing 
world. We evaluated the safety and immunogenicity of a new 
PRP-CRM197 conjugate Hib vaccine (Vaxem Hib, Chiron 
Vacdnes), compared with theHibTITER vaccine (Wyeth-
Lederle Vaccines), following the World Health Organisation 
(WHO)'s accelerated schedule which allows 4-week intervals 
between doses. 
Study design. A phase II, observer-blind, multicentre, 
randomised, controlled, non-inferiority study. 
Methods. In total, 331 babies were immunised with either 
Vaxem Hib (N = 167) or HibTITER (N = 164) vaccine at 6, 10 
and 14 weeks of age, in parallel with oral polio, diphtheria-
tetanus-pertussis and hepatitis B vaccines. Post-
immunisation reactions were recorded after each 
immunisation and arfollow-up visits. Anti-polyribosyl-
ribitol phosphate (PRP) antibodies were measured using 
enzyme-linked immunosorbent assays (ELISAs) before and 1 
month after the third immunisation. 
Haemophilus influenzae type b (Hib) remains the principal cause 
of invasive bacterial diseases in under 5-year-olds in 
developing countries.1·'In those few developing countries 
where Hib vaccines are being used, the vaccines have proven 
to be effective in reducing transmission rates and protecting 
children at risk from invasive Hib diseases.4•5 
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Results. Overall, there was no significant difference in the 
anti-PRP levels between the two groups .. One month after the 
third immunisation, 76% of vacdnees in the Vaxem Hib 
group and 70% in the HibTITER group hadanti-PRP 
antibody mres i:: 1.0 vg/ tnl, while 96% of the Vaxem l-Iib 
group and.90% of the HibTITER gn;mp d.e!l}onstrated a),lt1-
PRP antibody titres;:: 0.15 vg/ml. The geometric me<t:ntitre 
at day 90 was 3.77 pg/ml for the VaxemHib and 3.0 Jlg/Inl 
for the HibTITER groups. Although the Vaxem Hib vaccine 
produced more redness (6% versus 1 %; p = 0.006) and 
swelling (5% versus 1%, p = 0.037), overall it was well 
tolerated compared with the B:ibTITER vaccine. There wa~ 
no significant difference in vaccine-relateq elevated 
temperature (;:: 38°(:) between the two groups (p = 0. 11), 
Conclusion. Both vaccines showed comparable safety llJ:\d 
immunogenicity profiles when administered to SouthAfrican 
babies at 6, 10 and 14weeks of age. 
S Afr Med T 2004; 94: 43-46. 
South Africa introduced universal Hib vaccination into the 
Expanded Programme on Immunisation (EPI) in July 1999.' A 
recent pre-immunisation study/ conducted in Cape Town, 
indicated that Hib.accounted for 86.5% of all the H. influenzae 
cases, 97.3% of meningitis cases, 71.4% of pneumonia cases and 
50% of septicaemia cases.' The incidence rates for all invasive 
Hib infections were found to be 169 and 47 per 100 000 
population for children< 1 and< 5 years, respectively.' These 
figures are no different from those in many other developing 
countries where there is a high burden of Hib diseases.'·' 
Hib vaccines contain a capsular polysaccharide, polyribosyl-
ribitol phosphate (PRP), which is the major virulence factor,' 
and a target for eliciting protective antibodies (anti-PRP) 
against Hib disease.8-1° Current Hib vaccines contain 
polysaccharide antigens chemically conjugated to a carrier 
protein (derived from either Corynebacterium diphtheriae, 
Clostridium tetani, or N. meningitidis) to enhance their 
immunogenicity and boost immunological memoryY·13 
South Africa has adopted the World Health Organisation 
(WHO)'s accelerated 4-week interval immunisation schedule, 
whereby children are vaccinated against polio, diphtheria-
tetanus-pertussis, hepatitis B and Hib diseases at the ages of 6, 
10 and 14 weeks. In this study, we evaluated the safety and 
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immunogenicity of a new PRP-CRM197 conjugate Hib vaccine 
(Vaxem Hib, Chiron Vaccines), compared with the HibTITER 
vaccine (Wyeth-Lederle Vaccines), following the WHO's 
accelerated immunisation schedule (4-week intervals between 
doses). 
Materials and methods 
Study design and study area 
This was a phase II, observer-blind, multicentre, randomised, 
controlled, non-inferiority study, conducted in three different 
clinics: Phedisong 1 (Ga-Rankuwa), Hebron(Hebron) and 
Boekenhout (Mabopane), all of which are situated north-west 
of Pretoria, South Africa. 
Vaccines 
The investigational vaccine was the Hib b conjugate vaccine, 
Vaxem Hib (Chiron Vaccines, Siena, Italy). The chemistry of 
this vaccine was based on controlled hydrolysis of the PRP 
polysaccharide to oligosaccharides, followed by selective 
activation of the reducing end and subsequent coupling to the 
carrier protein, through an adipic acid spacer.14 The non-toxic 
mutant of diphtheria toxin, CRM197, was used as a protein 
carrier. In the final vaccine formulation, aluminium hydroxide 
was used as an adjuvant. 
The pre-clinical and clinical development of this vaccine 
showed a high level of tolerability and immunogenicity,t'·15 and 
allowed it to be registered for use in infants and children under 
the age of 12 months, with an 8-week interval between doses. 
Each dose of Vaxem Hib contains 10 pg of capsular 
oligosaccharide of Hib conjugated to approximately 25 pg of 
carrier protein, mutant diphtheria CRM197, and the final 
formulation contains 0.05 mg of thiomersal, 1 mg of aluminium 
hydroxide and sodium phosphate buffer (pH = 7) in a 0.5 ml 
volume. 
The comparative vaccine was the American Home Product 
HibTITER vaccine (Wyeth-Lederle Vaccines, USA). Each 0.5 ml 
dose contains 10 }lg of purified Hib capsular antigen and 
approximately 25 pg of diphtheria CRM197 protein conjugate, 
dissolved in 0.9% sodium chloride. The HibTITER is indicated 
for the immunisation of babies and children aged 6 weeks - 5 
years, against Hib diseases. The HibTITER vaccine has the 
same carrier protein, CRM197, as the Vaxem Hib vaccine, but 
lacks the aluminium hydroxide adjuvant in the final 
formulation. ..... 
~ Ethics and consent 
The study protocol was approved by the Research and Ethics 
Committee of the Faculty of Medicine of the Medical 
University of Southern Africa (MEDUNSA) and the Medicines 
Control Council of South Africa. Parents or legal guardians of 
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the subjects were adequately informed of the study, and only 
babies of parents and legal guardians who signed consent 
forms were recruited into the study. 
Subjects' enrolment and selection criteria 
A total of 331 healthy South African babies who were 
candidates for primary vaccination according to the EPI 
schedule were recruited, and received either Vaxem Hib 
vaccine (N = 167, 89 male and 78 female, mean age 47.5 days), 
or HibTITER vaccine (N = 164, 77 male and 87 female, mean 
age 47.4 days). Subjects were included if they were 6 - 8 
weeks of age and in good health, as determined by medical 
history, physical examination and clinical assessment. 
Vaccination protocols 
Each of the study vaccines was injected intramuscularly in the 
anterolateral muscle of the right thigh. The other routine infant 
EPI vaccines (i.e. diphtheria-tetanus-pertussis (DTwP), hepatitis 
B vaccine (HBV) and oral polio vaccine (OPV)), were 
administered concomitantly, but separately, following standard 
procedures. DTwP was given as an intramuscular injection in 
the anterolateral muscle of the left thigh, HBV was 
administered in the right deltoid r-egion, and OPV was given 
orally. 
Randomisation and blinding 
Randomisation was done using a 1:1 ratio and was stratified by 
immunisation centre. To ensure observer blinding, only 
designated unblinded study staff who had no access to the 
study subjects or to their records had access to the 
randomisation list for vaccine assignment. The unblinded staff 
were instructed not to reveal (except in an emergency) the 
identity of the study vaccines to the parents or legal guardians 
or to the other blinded personnel (investigator, study nurse, 
etc.) involved in monitoring or conducting the study. 
Evaluating post-immunisation reactions 
Babies were observed for signs and symptoms of local or 
systemic reactions at the clinic (30 minutes after each of the 
three vaccine administrations) by the study personnel and at 
home (2 - 3 days after immunisation) by the parent or legal 
guardian and/or study nurse at follow-up visits. 
Laboratory methods 
Collection of specimens 
Samples of venous blood (2 - 3 ml) for antibody assays were 
drawn before the first immunisation and 4 - 6 weeks after the 
third immunisation. The clotted blood was stored at 2 - soc 
and centrifuged within 12 hours. Serum samples were stored 
at -20°C until shipped in dry ice to Chiron laboratories, Siena, 
Italy. 
Measurement of serum antibody titres 
The anti-PRP antibody assays were performed at the Chiron 
laboratories, Siena, Italy, using a modified enzyme-linked 
immunosorbent assay (ELISA) technique.16 The Food and Drug 
Administration (FDA) standard reference sera, with known 
antibody titres, were used. Measures of immunogenicity were 
anti-PRP antibody titres 2': 0.15 ].lg/ml (for protection) and 2 1.0 
pg/ml (for long-lasting protection). 
Statistical methods 
This was designed as a non-inferiority study, adequately 
powered to exclude differences in percentage of subjects with 
post-immunisation anti-PRP titres 2': 1.0 ].lg/ml greater than 
15% by means of a two-sided 90% confidence interval (CI). 17 
Descriptive statistics (mean, standard deviation, median, 
minimum and maximum) were calculated. Incidences of local 
and systemic reactions were compared between vaccine groups 
using the chi-square test, or Fisher's exact test. The geometric 
mean titres (GMTs) and 95% Cis were calculated by 
exponentiating (base 10) the least squares means of the 
logarithmically transformed (base 10) titres and their 95% Cis 
obtained from a one-way analysis of variance (AN OVA) with 
factor for vaccine group. The geometric mean ratios (GMRs) 
and 90% Cis were calculated by exponentiating the difference 
between the least squares means and the associated 90% CJ 
from the same AN OVA. 
Results 
Immunisations schedules 
Initially, 167 babies received Vaxem Hib vaccine and 164 
received HibTITER vaccine. However, 17 subjects (1 0%) in the 
Vaxem Hib group were eventually excluded after receiving the 
first dose, 4 because of initial inappropriate enrolment and 13 
because they were lost to follow-up. Similarly, 32 subjects 
(20%) in the HibTITER group were eventually excluded, for 
several reasons: 24 because they were lost to follow-up, 6 
because of protocol deviation or inappropriate initial 
enrolment, 1 due to an adverse event, and 1 because of 
withdrawal of consent. Therefore, a total of 150 subjects (90%) 
in the Vaxem Hib group and 132 subjects (80%) in the 
HibTITER group completed the immunisation protocols, and of 
these babies, 143 (86%) in the Vaxem Hib group and 126 (77%) 
in the Bib TITER group were included in the immunogenicity 
analyses (Fig. 1). 
Primary and secondary post-immunisation response 
At baseline there was no significant difference between study 
subjects with anti-PRP antibody titres 21.0 ].lg/ml in the two 
groups (14% v. 15%) in the subset of babies evaluated for 
immunogenicity (Fig. 1). At day 90, 1 month after the third 
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Fig. 1. Primary (anti-PRP ( 1.0 Fgfml) and secondary (anti--PRP 
2': 0.15 Fg/ml) immunogenicity measures. 
immunisation, 76% of vaccinees in the Vaxem Hib group and 
70% of those in the HibTTTER group demonstrated a titre 2 1.0 
].lg/ml, and this difference was not statistically significant. 
Since the lower limit of the CI was well above the pre-specified 
value of -15% (90% Cl: -3'Yo- 15%), non-inferiority was 
demonstrated. 
At baseline there was a significant imbalance for both 
percentage of subjects with anti-PRP titres 2': Cl.l5 pg/ml and 
anti-PRP GMT, with higher values in the HibTTTER group. 
After vaccination, the Vaxem Hib vaccine group was slightly 
more immunogenic when anti-PRP antibody titres 2 0.15 
pg/ml were used as a measure 1 month after the last dose. It 
was found that 96% in the Vaxem Hib group and 90% in the 
HibTJTER group had anti-PRP antibody titres 2': 0.15 ].lg/ml 
1 month after the third immunisation in the same subset of 
subjects evaluated for immunogenicity (Fig. 1). Moreover, the 
post-vaccination GMT for the Vaxem Bib group was 3.77 
].lg/ml and 3.0 ].lg/ml for the HibTJTER group, and the 90% Cl 
for their ratio included 1, i.e. the difference was not statistically 
significant. The ratio of Vaxem Hib vaccine to HibT!TER 
vaccine GMRs was 1.77 (90% CI: 1.1- 2.85). 
Post-immunisation reactions 
In both vaccine groups, local and systemic reactions were mild 
and transient and resolved without sequelae. Although the 
Vaxem Hib vaccine produced more redness (6% versus 1%, 
p = 0.006) and swelling (5% versus 1%, p = 0.037) than the .. 
HibTITER vaccine, overall it was well tolerated. Finally, 6% of 
subjects in the Vaxcm Hib group demonstrated a post-
vaccination fever (temperature? 38°C) versus 2% in the 
HibTITER group, which was not statistically significant 




The widespread application of Hib conjugate vaccines in the 
USA has resulted in the decline of the number of reported Hib 
invasive cases by 99% between 1987 and 1997.18 In The Gambia, 
the efficacy of the conjugate vaccine was 95% for the 
prevention of all invasive Hib diseases.' These are encouraging 
results and clearly demonstrate the feasibility of eliminating 
Hib diseases through effective immunisation programmes. 
However, significant reduction in childhood morbidity and 
mortality from Hib diseases will only occur when vaccination 
coverage rates with Hib conjugate vaccines have been achieved 
in most of the developing world. The major constraint on 
introducing these vaccines is cost. One study investigated the 
potential of maximising the use of these vaccines in poorer 
countries by diluting a Hib conjugate vaccine 10-fold in a 
multidose vial of DTwP vaccine, and the diluted vaccine was 
found to be as immunogenic and safe as the full dose.19 
Many developing countries vaccinate infants according to 
the WHO's accelerated 4-week interval schedule. An ideal Hib 
conjugate vaccine for the developing world should be easily 
integrated into this schedule, without compromising its 
immunogenic potency, and should be compatible with other 
childhood vaccines. We found comparable immunogenicity 
results for the Vaxem Hib vaccine and the HibTITER vaccine 
for anti-PRP antibody titres ~ 1.0 vg/ml before and after the 
immunisation course, and non-inferiority of the Vaxem Hib 
vaccine was demonstrated (Fig. 1). However, overall the 
Vaxem Hib vaccine was slightly more immunogenic than the 
HibTITER vaccine, perhaps due to aluminium hydroxide 
adjuvant, which is not present in the HibTITER. 
Further, the Vaxem Hib vaccine was well tolerated, despite 
producing slightly more redness and swelling at the site of 
injection compared with the HibTITER vaccine. Increased local 
reaction at the injection site is a well-known and normal 
consequence of an adjuvant, in this case included in the Vaxem 
Hib vaccine but not in the HibTITER vaccine. 
In conclusion, Vaxem Hib and HibTITER vaccines 
demonstrated comparable safety and immunogenicity profiles 
when administered to South African infants at 6, 10 and 14 
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weeks of age. Infants in countries such as South Africa with a 
high endemicity of Hib invasive diseases need to be protected 
with an optimal immunogenic vaccine in early childhood as 
provided by the WHO accelerated immunisation schedule. 
We thank staff members of Phedisong 1 clinic, Hebron clinic, and 
Boekenhout clinic for their warmth and support. 
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